Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study

Satoshi IwataDepartment of Infectious Diseases; School of Medicine; Keio University; Shinjuku-ku, Tokyo, JapanCorrespondence[email protected]

Naohisa KawamuraOsaka Rosai Hospital; Sakai-city, Osaka, Japan

Haruo KurokiSotobo Children's Clinic; Medical Corporation Shigyo-no-kai; Isumi-city, Chiba, Japan

Yasunobu TokoedaShonan-Kamakura Clinic; Kamakura-city, Kanagawa, Japan

Mitsunobu MiyazuMeitetsu Hospital; Nagoya-city, Aichi, Japan

Asayuki IwaiKagawa Children's Hospital; Zentsuji-City, Kagawa, Japan

Tomohiro OishiNiigata University Medical and Dental Hospital; Niigata-City, Niigata, Japan

Tomohide SatoJapan Vaccine Co. Ltd.; Chiyoda-ku, Tokyo, Japan

Akari SuyamaGlaxoSmithKline K.K.; Shibuya-ku, Tokyo, Japan

Nancy FrançoisGSK Vaccines; Wavre, Belgium

Fakrudeen ShafiGSK Pharmaceuticals; Bangalore, India

Javier Ruiz-GuiñazúGSK Vaccines; Wavre, Belgium

Dorota BorysGSK Vaccines; Wavre, Belgium

Your download is now in progress and you may close this window